December 30th to Turkey from Sinovac developed against the coronavirus vaccine efficacy rates appeared to give different results in different countries. Vaccine efficacy rate in Turkey, different outcomes in Brazil and Indonesia.
Causing the death of more than 1.9 million people worldwide coronavirus epidemic developed by Sinovac company against; Turkey, had been ordered by countries such as Brazil and Indonesia. 3 million doses of the vaccine came to our country on 30 December.
The effectiveness rates of the vaccine developed by Sinovac were announced by different countries at different rates. According to the news in BirGün, Indonesia announced the phase 3 results of Sinovac’s vaccine. Accordingly, the vaccine in Indonesia 65.3% impact rate as announced.
Sinovac’s vaccine’s rate of effectiveness varies
Indonesia is among the countries that approved the vaccine developed by Sinovac. Penny K. Lukito, President of the Country’s Food Safety Agency, Above 50% efficiency rate stated that they gave consent to the vaccine because it was.
Intermediate results of the vaccine in our country efficiency rate 91.25% was explained as. It was stated that this rate was 78% in Brazil. Health Minister Fahrettin Koca said that the 78% efficiency rate in Brazil belongs to moderate cases. Husband stated that in severe cases, this efficiency rate increased to 100%.
Sinovac, to overcome the recent reporting on Indonesia, Turkey and Chile are awaiting the results of the testing period. Having the Sinovac vaccine in our country, Assoc. Dr. İlyas Yolbaş is at no serious side effects were found and Yolbaş had been found to have produced sufficient antibodies at the end of 3 weeks.
RELATED NEWS
Scientific Committee Member Prof. Dr. 3rd Wave Explanation in Coronavirus by Tevfik Özlü
In addition, President Recep Tayyip Erdoğan, in his press release after today’s cabinet meeting, emphasized the vaccination efforts in our country. Thursday or Friday He said it would start.
Source :
https://www.birgun.net/haber/etkinlik-orani-turkiye-nin-aldigi-sinovac-asisinda-uc-ulke-uc-farkli-sonuc-329976
$(function(){
//facebook window.fbAsyncInit = function() { FB.init({ appId : '1037724072951294', xfbml : true, version : 'v2.5' }); };
(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/tr_TR/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));
$('body').on({ click: function() { // facebook save button ajax FB.XFBML.parse(); } }, '.facebook-save');
// share scroll if ($('.content-sticky').length > 0) { if ($(window).width() >= 768) { $(window).on('scroll', function () { var scrollTop = $(this).scrollTop(); $('article').each(function () { if (scrollTop >= ($(this).find('.content-body').offset().top - 76)) { $(this).find('.content-sticky').addClass('sticky'); if (scrollTop >= ($(this).find('.content-body').offset().top + $(this).find('.content-body').height() - ($(this).find('.content-sticky').height() + 92))) { $(this).find('.content-sticky').removeClass('sticky'); $(this).find('.content-sticky').css({'bottom': '0px', 'top': 'auto'}); } else { $(this).find('.content-sticky').addClass('sticky').css({ 'bottom': 'initial', 'top': '76px' }); } } else { $(this).find('.content-sticky').removeClass('sticky').css({'bottom': 'auto', 'top': '0'}); } }); }); } }
// share click $('body').on({ click: function (){ var $this = $(this), dataShareType = $this.attr('data-share-type'), dataType = $this.attr('data-type'), dataId = $this.attr('data-id'), dataPostUrl = $this.attr('data-post-url'), dataTitle = $this.attr('data-title'), dataSef = $this.attr('data-sef');
switch(dataShareType) { case 'facebook': FB.ui({ method: 'share', href: dataSef, }, function(response){ if (response && !response.error_message) { updateHit(); } });
break;
case 'twitter': shareWindow('https://twitter.com/intent/tweet?via=webtekno&text="+encodeURIComponent(dataTitle) + " %E2%96%B6 ' + encodeURIComponent(dataSef)); updateHit(); break;
case 'gplus': shareWindow('https://plus.google.com/share?url=" + encodeURIComponent(dataSef)); updateHit(); break;
case "mail': window.location.href="https://www.webtekno.com/mailto:?subject=" + encodeURIComponent(dataTitle) +'&body='+ encodeURIComponent(dataSef); //updateHit(); break;
case 'whatsapp': window.location.href="whatsapp://send?text=" + encodeURIComponent(dataTitle) +' %E2%96%B6 '+ encodeURIComponent(dataSef); updateHit(); break; }
function shareWindow (url) { window.open(url, "_blank", "toolbar=yes, scrollbars=yes, resizable=yes, top=500, left=500, width=400, height=400"); }
function updateHit () { $.ajax({ type: "POST", url: dataPostUrl, data: {contentId: dataId, contentType: dataType, shareType: dataShareType}, success: function(data) {
if ($('.video-showcase').length > 0) { var $container = $('.video-showcase'); } else if ($('article[data-id="' + dataId + '"]').length > 0) { var $container = $('article[data-id="' + dataId + '"]'); } else if ($('.wt-share-item[data-id="' + dataId + '"]').length > 0) { var $container = $('.wt-share-item[data-id="' + dataId + '"]'); } else { $container = null; }
//var $container = dataType == 'video' ? $('.video-showcase') : $('article[data-id="' + dataId + '"]');
if ( $container != null && $container.length > 0 ) { var $badged = $container.find('.wt-share-badge-' + dataShareType);
var $headerCount = $('.content-header').find('.wt-share-count'), $containerCount = $container.find('.wt-share-count'), value = parseInt($containerCount.html()) + 1;
$container.data('share', value); //$containerCount.html(value);
if ($headerCount.length > 0) { //$headerCount.html(value); }
if ( $badged.length > 0 && (dataShareType == 'facebook' || dataShareType == 'twitter')) { if ($badged.hasClass('is-visible')) { //$badged.html(data); } else { //$badged.addClass('is-visible').html(data); } } }
} }); } } }, '.wt-share-button') });